Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan — PREDEMPARK  

Parkinson Disease Clinical Trial

Official title: Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan

Status Not yet recruiting

Clinical Trial Summary

Parkinson's disease (PD) is a common disease. Dementia will affect 80% of these patients during their evolution. In addition, treatments of motor signs have a potential impact on these disorders and conversely.

The purpose of this study is to show focal abnormalities in brain metabolism in the precuneus and posterior cingulate region are predictive of the onset of dementia within 2 years.

Clinical Trial Description

Cognitive impairment and dementia have become major factors of disability induced by Parkinson's disease. The prediction of dementia in any given patient may be useful for prognosis but also for discussion of setting up heavy therapeutic techniques, especially surgical. Currently, known predictors are disease severity, age and existence of pre-cognitive disorders; other assumptions are discussed. Among these, morphological imaging techniques (MRI) and functional techniques (MRI, PET) are proposed.

Use increasingly early of heavy, expensive and potentially ineffective surgical treatment in dementia makes it necessary to find independent, early and reliable markers of the onset of dementia in Parkinson's Disease. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Dementia
• Parkinson Disease

• NCT number: NCT02855021
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Claire THIRIEZ, MD
• Phone: (0)1 49 81 43 12
• Email: claire.thiriez@aphp.fr
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2016
• Completion date: September 2019